意大利HMGBiotech代理抗体蛋白

HMGBiotech is a biotech company founded by Marco E. Bianchi, a leading scientist in the HMGB field.

HMGB1 is a component of the cell nucleus, with multiple functions in the organization and expression of the genome. When a cell dies because of an insult (a virus, a mechanical or chemical trauma, poisoning) HMGB1 is released and is picked up by receptors in nearby cells. In addition, cells under severe stress secrete HMGB1 even before dying. Surviving cells mount a firstline response -inflammation- and try to replace the dead cells and reconstruct the damaged tissue. HMGB1 promotes recovery and regeneration, for example of the heart after infarction. However, too much HMGB1 is associated to sepsis (excessive inflammation leading to acute distress and eventually death), arthritis, atherosclerosis, and cancer metastasis.

HMGBiotech srl provides reagents, services and ideas to other researchers and companies active in this promising field. It also helps the Bianchi lab in developing assays and reagents.

HMGBiotech has R&D and production unit within OSR in via Olgettina 58, 20133 Milano, Italy

HMGBiotech是一家生物技术公司，由HMGB领域的领先科学家马可·E·比安奇创立。
HMGB1是细胞核的一个组成部分，在基因组的组织和表达中具有多种功能。当一个细胞因侮辱（病毒、机械或化学创伤、中毒）而死亡时，HMGB1被释放，并被附近细胞的受体摄取。此外，处于严重压力下的细胞甚至在死亡之前就分泌HMGB1。存活的细胞会产生第一线反应——炎症，并试图替换死亡细胞，重建受损组织。HMGB1促进恢复和再生，例如梗死后的心脏。然而，过多的HMGB1与败血症（过度炎症导致急性窘迫并最终死亡）、关节炎、动脉粥样硬化和癌症转移有关。
HMGBiotech srl为活跃在这一有希望的领域的其他研究人员和公司提供试剂、服务和想法。它还帮助Bianchi实验室开发分析和试剂。
HMGBiotech在意大利米兰via Olgettina 5820133的OSR内设有研发和生产部门